Risikowertung und therapeutische Bedeutung des Pulsdruckes bei primärer Hypertonie

Summary: Analysis of the results raised in the Framingham and the MRFIT study have clearly shown that increased pulse pressure is an independent cardiovascular risk factor. This is valid for all age groups and both sexes. The risk increases with pulse pressures over 60 - 65 mmHg for office blood pressure and 53 mmHg for 24-h-mean of ambulatory blood pressure. Pulse pressure is strongly correlated with systolic blood pressure and will be highest in case of isolated systolic hypertension. Urinary albumin excretion and left ventricular hypertrophy are closely associated with pulse pressure. With elevated pulse pressure cardiovascular risk is increased 2- to 4-fold in relation to age and endpoint. The risk of myocardial infarction is raised more if pulse pressure is associated with low mean arterial blood pressure while risk of stroke is increased with wide pulse pressure and high mean arterial pressure. The risk of pulse pressure can be seen in normotensives and in early pregnancy. Therapeutic management of pulse pressure will be similar to that of systolic blood pressure, since normalization of systolic blood pressure will also lower or normalize pulse pressure. Results of preliminary studies suggest that diuretics are superior to other drugs in decreasing pulse pressure. An increase of pulse pressure during therapy should be avoided since each 10 mmHg increase in pulse pressure will raise the risk of stroke and myocardial infarction about 24 % and 32 %.

Literatur

• 1 Cushman W C, Materson B J, Williams D W. et al . Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial.  Hypertension. 2001;  38 953-957
• 2 Domanski M J, Davis B R, Pfeffer M A. et al . Isolated systolic hypertension. Prognostic Information Provided by Pulse Pressure.  Hypertension. 1999;  34 375-380
• 3 Domanski M J, Mitchell G, Pfeffer M A. et al . Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT).  JAMA. 2002;  287 2677-2683
• 4 Domanski M J, Normann J, Wolz M. et al . Cardiovascular risk assessment using pulse pressure in the first national health and nutrition examination survey (NHANES I).  Hypertension. 2001;  38 793-797
• 5 Fagard R H, Pardaens K, Staessen J A. et al . The pulse pressure-to-stroke index ratio predicts cardiovascular events and death in uncomplicated hypertension.  J Am Coll Cardiol. 2001;  38 227-231
• 6 Fang J, Madhavan S, Alderman M H. Pulse pressure: a predictor of cardiovascular mortality among young normotensive subjects.  Blood pressure. 2000;  9 260-266
• 7 Gerdts E, Papademetriou V, Palmieri V. et al . Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).  Am J Cardiol. 2002;  89 399-402
• 8 Jokiniitty J M, Majahalme S K, Kähönen M A. et al . Pulse pressure is the best predictor of future left ventricular mass and change in left ventricular mass: 10 years of follow-up.  J Hypertens. 2001;  19 2047-2054
• 9 Klassen P S, Lowrie E G, Reddan D N. et al . Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis.  JAMA. 2002;  287 1548-1555
• 10 Millar J A, Lever A F, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial.  J Hypertens. 1999;  17 1065-1072
• 11 Ohkubo T, Hozawa A, Imai Y. Prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke.  Circulation. 2001;  104 E160
• 12 O‘Rourke M, Frohlich E D. Pulse Pressure: Is this a clinically useful risk factor?.  Hypertension. 1999;  34 372-374
• 13 Pedrinelli R, Dell’Omo G, Penno G. et al . Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men.  Hypertension. 2000;  35 48-54
• 14 Safar M E, Levy B I, Laurent S. et al . Hypertension and the arterial system: clinical and therapeutic aspects.  J Hypertens. 1990;  8 S113-S119 (suppl 7)
• 15 SHEP Cooperative Research Group . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP).  JAMA. 1991;  265 3255-3264
• 16 Staessen J A, Fagaro R, Thijs L. et al . Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.  Lancet. 1997;  350 757-764
• 17 Thadhani R, Ecker J L, Kettyle E. et al . Pulse pressure and risk of preeclampsia: a prospective study.  Obstetrics and gynecology. 2001;  97 515-520
• 18 Vaccarino V, Berger A K, Abramson J. et al . Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program.  Am J Cardiol. 2001;  88 980-986
• 19 Vasan R S, Larson M G, Leip E P. et al . Impact of high-normal blood pressure on the risk of cardiovascular disease.  N Engl J Med. 2001;  345 1291-1297
• 20 Vasan R S, Massaro J M, Wilson P WF. et al . Antecendent blood pressure and risk of cardiovascular disease. The Framingham Heart Study.  Circulation. 2002;  105 48-53
• 21 Verdecchia P, Schillaci G, Borgioni C. et al . Ambulatory pulse pressure. A potent predictor of total cardiovascular risk in hypertension.  Hypertension. 1998;  32 983-988
• 22 Zanchetti A, Bond M G, Hennig M. et al . Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.  J Hypertens. 1998;  16 949-961
• 23 Deutsche Liga zur Bekämpfung des hohen Blutdruckes, deutsche Hypertoniegesellschaft . Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie.  Dtsch Med Wochenschr. 2001;  126 (Suppl 4)